雷美西维尔通过将TAL1合到TRAF6来抑制内皮激活和动脉样硬化
Hanning Zhang1, Ruru Li1, Qianqian Huo2
1Shandong First Medical University, Jinan, China.
Journal of translational medicine
|July 2, 2025
概括
抗病毒药物remdesivir通过恢复TAL1-TRAF6相互作用,减少内皮细胞活化和减少小鼠的动脉样硬化病变来有效治疗动脉样硬化. 这为这种复杂的心血管疾病提供了一个新的治疗策略.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 动脉样硬化涉及复杂的内皮功能障碍和炎症.
- 目前对动脉样硬化的治疗方法有限.
- 这项研究调查了remdesivir,一种抗病毒药物,其在治疗动脉样硬化的潜力.
研究的目的:
- 探索remdesivir在治疗动脉样硬化的新应用.
- 调查雷梅西维尔对内皮细胞激活和动脉样硬化病变发展的影响.
主要方法:
- 给食用西方饮食的ApoE-/-小鼠注射雷德西维尔.
- 评估了动脉样硬化病变和VCAM-1表达.
- 研究了remdesivir对氧化LDL诱导的内皮细胞激活,单细胞粘附和ROS生产 in vitro的影响.
- 研究了人静脉内皮细胞 (HUVECs) 中TAL1和TRAF6之间的相互作用.
- 在小鼠中利用siRNA进行TAL1干扰和AAV介导的TAL1过度表达.
主要成果:
- 雷梅西维尔显著降低了阿波E-/-小鼠的动脉样硬化病变和VCAM-1表达.
- 雷梅西维尔减弱了氧化LDL诱导的内皮激活,单细胞粘附和ROS产生.
- 雷梅西维尔恢复了TAL1-TRAF6的相互作用,并通过降低TRAF6的无化,减少了内皮活化.
- 内皮特异性TAL1过度表达也减少了动脉样硬化病变和VCAM-1表达.
结论:
- 雷梅西维尔通过恢复TAL1-TRAF6相互作用和减少内皮细胞激活来阻止动脉样硬化的进展.
- 这些发现使得雷梅西维尔成为动脉样硬化的有前途的治疗药物.
更多相关视频
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
227
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
227
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Atherosclerosis III: Management
41
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
41
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
263
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
263
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Atherosclerosis I: Introduction
93
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
93


